The Column Group Crossover Fund (TCGX)
Overview
The Column Group Crossover Fund (TCGX) is a venture capital firm investing in early-stage biotechnology companies. TCGX is the first crossover fund under The Column Group (TCG) ecosystem, dedicated to investing in later-stage private and public drug discovery companies. Launched in 2021, TCGX focuses on innovative pre-IPO and public companies, aiming to support the translation of cutting-edge science into products that will make a meaningful difference for patients. TCGX operates independently within the TCG ecosystem, which includes TCG Platform funds, TCG Opportunity funds, TCG Labs-Soleil, and TCG Crossover. TCGX's goal is to support the translation of cutting-edge science into products that will make a meaningful difference for patients. TCGX is operationally independent of The Column Group (TCG).
Investment Focus
- Innovative drug discovery companies
- Focus on unmet medical needs
- Pre-IPO and public companies
Portfolio Companies
Reach The Column Group Crossover Fund (TCGX) directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about The Column Group Crossover Fund (TCGX)
What sectors does The Column Group Crossover Fund (TCGX) invest in?
The Column Group Crossover Fund (TCGX) invests in Healthcare, Life Sciences, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in California, United States. The Column Group Crossover Fund (TCGX) is listed as a venture capital in the ConnectSafely investor database.
What stage does The Column Group Crossover Fund (TCGX) invest at?
The Column Group Crossover Fund (TCGX) backs companies at Early Stage, Growth, Late Stage and Pre-IPO, writing cheques of 10M - 50M.
Which regions does The Column Group Crossover Fund (TCGX) invest in?
The Column Group Crossover Fund (TCGX) invests across United States, Europe and China.
What companies has The Column Group Crossover Fund (TCGX) invested in?
The Column Group Crossover Fund (TCGX)'s portfolio includes Neurona Therapeutics, Synthekine, RAPT Therapeutics, ORIC Pharmaceuticals, Remix Therapeutics and Accent Therapeutics.
Last updated · Source: ConnectSafely investor database
